The diazoxide derivative 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-S,S-dioxide (IDRA21) enhances memory and learning in rodents, most likely by potentiating AMPAergic synaptic activity. We examined IDRA21's effect upon AMPAergic synaptic currents and whole-cell glutamate currents in cultured rat hippocampal neurons to determine whether IDRA21 was a partial modulator of AMPA receptor desensitization and deactivation. Comparable to cyclothiazide, IDRA21 prolonged AMPAergic autaptic currents (5.6 times control, EC 50 150 M) and slowed the rate of AMPA deactivation (3 times control) following 1-ms applications of 1 mM glutamate to excised, outside-out membrane patches. IDRA21 also augmented autaptic GABA currents by 27 ؎ 8.1%, although it had two opposing effects, reducing the peak amplitude versus prolonging autaptic GABA currents. IDRA21 (200 M) inhibited whole-cell GABA currents elicited by exogenously applied 1 mM GABA by 41 ؎ 11%. At sufficient concentrations, IDRA21 reduced AMPA receptor desensitization and slowed the rate of deactivation, most consistent with full agonist activity with lower potency compared to cyclothiazide. IDRA21 slightly augments GABAergic synaptic currents. 1998 Academic Press
INTRODUCTION
The hippocampus is involved in learning and memory, possessing excitatory synaptic circuitry dependent extensively upon AMPA-type glutamate receptors. Plasticity of hippocampal synapses is thought to be necessary for learning and memory, and synapsespecific, activity-dependent strengthening of hippocampal AMPAergic synaptic responses (long-term potentiation, LTP) is a cellular mechanism that could confer such synaptic plasticity (Bliss and Collingridge, 1993) . Consequently, there has been interest in benzoylpiperidines (Staubli et al., 1994a) and the diazoxide derivative 7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-S,S-dioxide (IDRA21) (Bertolino et al., 1993) as memory and cognitive enhancing drugs with potential usefulness to patients with memory deficits (dementia), because they facilitate LTP in vitro and in vivo (Staubli et al., 1994b; Arai et al., 1996a) and improve performance of animals in experimental learning and memory tests (Staubli et al., 1994a; Zivkovic et al., 1995; Uzunov et al., 1995) . These drugs have in common the ability to inhibit AMPA receptor desensitization (Bertolino et al., 1993; Arai et al., 1996b) and slow the rate of AMPA receptor deactivation (Patneau et al., 1993; Partin et al., 1996; Arai et al., 1996b) , resulting in potentiation of AMPA-gated currents; hence the presumed basis for IDRA21's favorable effect upon experi-
